Effect of Pioglitazone on Insulin Resistance and Atherosclerosis in Renal Allograft Recipients Without Diabetes
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
|Official Title:||A Randomized Controlled Trial of Pioglitazone on Insulin Resistance, Insulin Secretion and Atherosclerosis in Renal Allograft Recipients Without History of Diabetes|
- Insulin Resistance and Insulin Secretion [ Time Frame: 1 year ] [ Designated as safety issue: No ]
- carotid intima-media thickness [ Time Frame: 1 year ] [ Designated as safety issue: No ]
|Study Start Date:||November 2004|
|Study Completion Date:||November 2007|
|Primary Completion Date:||November 2007 (Final data collection date for primary outcome measure)|
The pioglitazone treatment group received 30mg pioglitazone at 2 weeks after renal transplantation for 12 months.
|No Intervention: 2|
This is a prospective, randomized, open-label study. The pioglitazone treatment group received 30mg pioglitazone at 2 weeks after renal transplantation for 12 months.
After treatment, we estimated insulin sensitivity index for transplantation,first phase and second phase insulin secretion, secretion area under the curve,and carotid intima-media thickness.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00598013
|Korea, Republic of|
|Yonsei University College of Medicine|
|Seoul, Korea, Republic of, 120-752|
|Principal Investigator:||Hyun Chul Lee, Doctor||Yonsei University|